Results 221 to 230 of about 35,674 (297)

Change of substance‐related hospitalisation in adolescents after cannabis legalisation in Thailand in 2022

Addiction, EarlyView.
Abstract Background and aims On 9 June 2022, Thailand changed its cannabis legislation, expanding access to individuals aged >18 years. Evidence suggests that such changes could increase the risk of cannabis use and related harms, and could influence patterns of use of other substances among adolescents.
Sirada Puetpaiboon, Songyos Rajborirug, Vorthunju Nakhonsri, Chumpol Ngamphiw, Peerapat Khunkham, Sissades Tongsima, Watcharapot Janpoung, Virasakdi Chongsuvivatwong   +7 more
wiley   +1 more source

Trends in Use of Medications for Opioid Use Disorder among Commercially Insured U.S. Surgical Patients, 2016 to 2022. [PDF]

Anesthesiology
Bicket MC, Qi X, Buchwalder K, Chua KP, Lagisetty P, Gunaseelan V, Waljee JF, Brummett CM, Li Y, Nguyen T.   +9 more
europepmc   +1 more source

Comparative effectiveness of alternative times to opioid agonist treatment taper initiation on taper completion and all‐cause mortality among people with opioid use disorder: A retrospective population‐based target trial emulation study in British Columbia, Canada, 2010–2020

Addiction, EarlyView.
Abstract Background and aims Opioid use disorder (OUD) treatment guidelines worldwide recommend opioid agonist treatment (OAT) as a long‐term, potentially indefinite treatment for managing OUD. However, many individuals express a strong interest in eventually tapering fully off treatment.
Ruyu Yan, Jeong Eun Min, Megan Kurz, Shaun R. Seaman, Paxton Bach, Sander Greenland, Paul Gustafson, Mohammad Ehsanul Karim, Lawrence McCandless, Robert William Platt, Uwe Siebert, María Eugenia Socías, Hui Xie, Bohdan Nosyk   +13 more
wiley   +1 more source

"Convenience, Quickness, and Compassion": Experiences of People Involved in the Criminal-Legal System Accessing Medications for Opioid Use Disorder Services From a Mobile Unit in Chicago. [PDF]

Health Expect
Martinford T, Watson DP, Messmer S, Rashid L, Staton M, Dennis ML, Grella CE, Elmes-Patel A.   +7 more
europepmc   +1 more source

Brain reward function in young people with cannabis use disorder: A functional magnetic resonance imaging study

Addiction, EarlyView.
Abstract Background and Aims Cannabis use disorder (CUD) affects ~50 million people globally. Neuroscientific theories suggest that a blunted neural response to non‐drug rewards is a hallmark of substance use disorders; however, this remains untested in CUD. The current study tested whether brain reward system responses to the anticipation and feedback
Martine Skumlien, Lisa‐Marie Greenwood, Arush Honnedevasthana Arun, Isabella Goodwin, Anastasia Paloubis, Tribikram Thapa Rana, Marianna Quinones Valera, Eugene McTavish, Gabrielle Abbott, Suraya Dunsford, Antonio Verdejo‐Garcia, Jessica Ramamurthy, Mark M. Schira, Nadia Solowij, Chao Suo, Valentina Lorenzetti   +15 more
wiley   +1 more source

Using narrative and informational messages to improve correctional professionals' attitudes toward medications for opioid use disorder. [PDF]

Health Justice
Harrell-Webber A, Zhao X, Horoszko UA, Murphy A, Smith L, Taxman FS.   +5 more
europepmc   +1 more source

Rurality weakens the positive association between the COVID-19 pandemic and substance use treatment involving medications for opioid use disorder. [PDF]

Drug Alcohol Depend Rep
Lofaro RJ, Confer LM, Bohler RM, Schwind JS.   +3 more
europepmc   +1 more source

Factors associated with the percentage of individuals who initiate and discontinue naltrexone as a relapse prevention pharmacotherapy in opioid use disorder: A systematic review, meta‐analysis and meta‐regression

Addiction, EarlyView.
Abstract Background and aims Naltrexone is a pharmacotherapeutic option for relapse prevention in opioid use disorder (OUD); however, studies highlight low rates of initiation and high rates of discontinuation as limiting its effectiveness. We aimed to (1) estimate the percentage of individuals with OUD who (having undergone withdrawal and wish to ...
Emmert Roberts, Elizabeth Sanderson, Thomas Santo Jr., Matthew Hickman, Michael Farrell, Louisa Degenhardt   +5 more
wiley   +1 more source

Pre-exposure prophylaxis (PrEP) and medications for opioid use disorder for persons who inject drugs: the CHORUS + randomized controlled trial study protocol. [PDF]

Addict Sci Clin Pract
Miller SE, Dukes KA, Damato-MacPherson C, Psaros C, Scott NA, Taylor JL, Muroff J, Winter MR, Skiba LE, Lugo H, Cruz R, Ruiz-Mercado G, Crawford ND, Mayer KH, Assoumou SA.   +14 more
europepmc   +1 more source